Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)

Chaigneau, L.; Patrikidou, Anna; Valentin, Thibaud; Linassier, Claude; Bay, Jacques Olivier; Zabotto, Laurence Moureau; Bompas, Emmanuelle; Piperno‐Neumann, Sophie; Penel, Nicolas; Alcindor, Thierry; Laigre, Maryline; Guillemet, Cécile; Salas, Sébastien; Hügli, Anne; Dômont, Julien; Sunyach, Marie Pierre; Lecesne, A.; Blay, Jean Yves; Nerich, Virginie; Isambert, Nicolás

doi:10.1634/theoncologist.2017-0136

Cited by 24 publications

(69 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of the BRAINSARC project was an optimal opportunity to develop a prognostic index for this heterogeneous group of diseases. Within the BRAINSARC project, we had identified a subset of patients with survival longer than 2 years [17]. Histology alone was not able to select for these patients as this group, other than ASPS and SFTs, also included leiomyosarcoma, synovialosarcomas and Ewing/PNET tumors.…”

Section: Discussionmentioning

confidence: 99%

“…Under the auspices of GSF-GETO, a project involving a multi-institutional retrospective analysis project of sarcoma patients with brain metastases (cerebral or meningeal lesions) was developed (BRAINSARC) [17]. Institutional ethics committee approval was obtained for each centre.…”

Section: Patient Cohort and Data Collectionmentioning

confidence: 99%

“…The retrospective data collection was limited to patients managed between January 1992 and March 2012, to ascertain homogeneity in histological diagnosis and classification, namely uniform use of the FNCLCC grading system [18], and to ensure adequate follow-up. The results of this analysis are published elsewhere [17]. Utilizing and enriching this GSF-GETO database, we developed the current project of implementation of the original GPA on sarcoma patients and development of a disease-specific index (Sarcoma-GPA).…”

Section: Patient Cohort and Data Collectionmentioning

confidence: 99%

“…Data collection procedures for the BRAINSARC project are described in detail elsewhere [17]. Specifically for the current project, data collection was completed, verified and annotated for the GPA components, notably age at BM diagnosis, Karnofsky performance status (KPS), number of brain lesions and presence of extracranial metastases (ECM), as well as for overall survival (OS).…”

Section: Patient Cohort and Data Collectionmentioning

confidence: 99%

“…Brain metastases in sarcoma patients is rather rare, with a reported incidence of < 1 to 8%. The French Sarcoma Group (GSF-GETO) has recently published the largest series to date of sarcoma patients with brain metastases, describing their characteristics, treatment modalities, prognostic factors and outcome [17]. This report identified leiomyosarcoma and liposarcoma as the most frequent histologies in sarcoma BM patients, and identified several characteristics of long survivors (younger age, unique lesions, lower grade tumors, better PS, longer time to development of brain metastases, higher use of local treatment modalities) [17].…”

mentioning

confidence: 99%

See 4 more Smart Citations

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

Patrikidou

Chaigneau²,

Isambert

et al. 2020

BMC Cancer

Self Cite

View full text Add to dashboard Cite

Background: Brain metastases from sarcomatous lesions pose a management challenge owing to their rarity and the histopathological heterogeneity. Prognostic indices such as the Graded Prognostic Assessment (GPA) index have been developed for several primary tumour types presenting with brain metastases (e.g. lung, breast, melanoma), tailored to the specifics of different primary histologies and molecular profiles. Thus far, a prognostic index to direct treatment decisions is lacking for adult sarcoma patients with brain metastases. Methods: We performed a multicentre analysis of a national group of expert sarcoma tertiary centres (French Sarcoma Group, GSF-GETO) with the participation of one Canadian and one Swiss centre. The study cohort included adult patients with a diagnosis of a bone or soft tissue sarcoma presenting parenchymal or meningeal brain metastases, managed between January 1992 and March 2012. We assessed the validity of the original GPA index in this patient population and developed a disease-specific Sarcoma-GPA index. Results: The original GPA index is not prognostic for sarcoma brain metastasis patients. We have developed a dedicated Sarcoma-GPA index that identifies a subgroup of patients with particularly favourable prognosis based on histology, number of brain lesions and performance status. Conclusions: The Sarcoma-GPA index provides a novel tool for sarcoma oncologists to guide clinical decisionmaking and outcomes research.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Patient Cohort and Data Collectionmentioning

confidence: 99%

Section: Patient Cohort and Data Collectionmentioning

confidence: 99%

Section: Patient Cohort and Data Collectionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

Patrikidou

Chaigneau²,

Isambert

et al. 2020

BMC Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

A retrospective analysis of the prognosis of Japanese patients with sarcoma brain metastasis

Toda¹,

Kobayashi²,

Kubota

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Background Bone and soft tissue sarcomas are rare tumors and extremely rarely metastasize to the brain. Previous studies have examined the characteristics and poor prognostic factors in cases of sarcoma brain metastasis (BM). Due to the rarity of cases of BM from sarcoma, limited data exist concerning the prognostic factors and treatment strategies. Methods A retrospective single‐center study was performed on sarcoma patients with BM. The clinicopathological characteristics and treatment options for BM of sarcoma were investigated to identify predictive prognostic factors. Results Between 2006 and 2021, 32 patients treated for newly diagnosed BM at our hospital were retrieved among 3133 bone and soft tissue sarcoma patients via our database. The most common symptom was headache (34%), and the most common histological subtypes were alveolar soft part sarcoma (ASPS) and undifferentiated pleomorphic sarcoma (25%). Non‐ASPS ( p = 0.022), presence of lung metastasis ( p = 0.046), a short duration between initial metastasis, and the diagnosis of brain metastasis ( p = 0.020), and the absence of stereotactic radiosurgery for BM ( p = 0.0094) were significantly correlated with a poor prognosis. Conclusions In conclusion, the prognosis of patients with brain metastases of sarcomas is still dismal, but it is necessary to be aware of the factors associated with a relatively favorable prognosis and to select treatment options appropriately.

show abstract

Soft tissue tumor imaging in adults: whole-body staging in sarcoma, non-malignant entities requiring special algorithms, pitfalls and special imaging aspects. Guidelines 2024 from the European Society of Musculoskeletal Radiology (ESSR)

Noebauer-Huhmann,

Vanhoenacker,

Vilanova

et al. 2024

Eur Radiol

View full text Add to dashboard Cite

Objectives The revised European Society of Musculoskeletal Radiology (ESSR) consensus guidelines on soft tissue tumor imaging represent an update of 2015 after technical advancements, further insights into specific entities, and revised World Health Organization (2020) and AJCC (2017) classifications. This second of three papers covers algorithms once histology is confirmed: (1) standardized whole-body staging, (2) special algorithms for non-malignant entities, and (3) multiplicity, genetic tumor syndromes, and pitfalls. Materials and methods A validated Delphi method based on peer-reviewed literature was used to derive consensus among a panel of 46 specialized musculoskeletal radiologists from 12 European countries. Statements that had undergone interdisciplinary revision were scored online by the level of agreement (0 to 10) during two iterative rounds, that could result in ‘group consensus’, ‘group agreement’, or ‘lack of agreement’. Results The three sections contain 24 statements with comments. Group consensus was reached in 95.8% and group agreement in 4.2%. For whole-body staging, pulmonary MDCT should be performed in all high-grade sarcomas. Whole-body MRI is preferred for staging bone metastasis, with [18F]FDG-PET/CT as an alternative modality in PET-avid tumors. Patients with alveolar soft part sarcoma, clear cell sarcoma, and angiosarcoma should be screened for brain metastases. Special algorithms are recommended for entities such as rhabdomyosarcoma, extraskeletal Ewing sarcoma, myxoid liposarcoma, and neurofibromatosis type 1 associated malignant peripheral nerve sheath tumors. Satisfaction of search should be avoided in potential multiplicity. Conclusion Standardized whole-body staging includes pulmonary MDCT in all high-grade sarcomas; entity-dependent modifications and specific algorithms are recommended for sarcomas and non-malignant soft tissue tumors. Clinical relevance statement These updated ESSR soft tissue tumor imaging guidelines aim to provide support in decision-making, helping to avoid common pitfalls, by providing general and entity-specific algorithms, techniques, and reporting recommendations for whole-body staging in sarcoma and non-malignant soft tissue tumors. Key Points An early, accurate, diagnosis is crucial for the prognosis of patients with soft tissue tumors. These updated guidelines provide best practice expert consensus for standardized imaging algorithms, techniques, and reporting. Standardization can improve the comparability examinations and provide databases for large data analysis.

show abstract

Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)

Cited by 24 publications

References 39 publications

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)

A retrospective analysis of the prognosis of Japanese patients with sarcoma brain metastasis

Soft tissue tumor imaging in adults: whole-body staging in sarcoma, non-malignant entities requiring special algorithms, pitfalls and special imaging aspects. Guidelines 2024 from the European Society of Musculoskeletal Radiology (ESSR)

Contact Info

Product

Resources

About